Optic nerve fiber damage is usually more severe in people with neuromyelitis optica spectrum disorder (NMOSD) than with idiopathic…
Articles by Marisa Wexler, MS
SinoMab BioScience has been cleared by Chinese regulators to launch a clinical trial for its experimental immune-suppressing therapy SN1011…
Authorities in China have granted IASO Biotherapeutics the go-ahead to begin clinical testing of the experimental CAR T-cell therapy…
A specific pattern of brain inflammation called BPCLI sometimes can occur in people with neuromyelitis optica spectrum disorder (NMOSD),…
Autoimmunity Modifying (AIM) Biologicals, an experimental platform that Aeterna Zentaris is developing to treat autoimmune diseases like neuromyelitis…
The European Commission has approved Uplizna (inebilizumab-cdon) to treat adults with neuromyelitis optica spectrum disorder (NMOSD) who test…
The European Commission is expected to propose a new governing framework for health data next month, called the European Health…
Blood levels of two proteins, GFAP and neurofilament light chain (NfL), may help predict the course of neuromyelitis optica…
A system that stages neuromyelitis optica spectrum disorder (NMOSD) based on damage to astrocytes — the specific brain cells…
The European Commission has approved Enspryng (satralizumab) for the treatment of people, 12 and older, with neuromyelitis optica…